Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100719-100719
Open Access | Times Cited: 170

Showing 1-25 of 170 citing articles:

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
Sylwester Drożdżal, Jakub Rosik, Kacper Lechowicz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100794-100794
Open Access | Times Cited: 262
Structural biology of SARS-CoV-2: open the door for novel therapies
Weizhu Yan, Yanhui Zheng, Xiao‐Tao Zeng, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 241
A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics
Lauren Forchette, William Sebastian, Tuoen Liu
Current Medical Science (2021) Vol. 41, Iss. 6, pp. 1037-1051
Open Access | Times Cited: 224
Temperature-Responsive Multilayer Films Based on Block Copolymer-Coated Silica Nanoparticles for Long-Term Release of Favipiravir
Li Xu, Xingxing Zhang, Zihan Chu, et al.
ACS Applied Nano Materials (2021) Vol. 4, Iss. 12, pp. 14014-14025
Closed Access | Times Cited: 145
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 136
COVID-19 drugs in aquatic systems: a review
Willis Gwenzi, Rangabhashiyam Selvasembian, Nnanake‐Abasi O. Offiong, et al.
Environmental Chemistry Letters (2022) Vol. 20, Iss. 2, pp. 1275-1294
Open Access | Times Cited: 75
Cardiovascular impact of COVID-19 with a focus on children: A systematic review
Moisés Rodríguez‐González, Ana Castellano‐Martínez, Helena María Cascales-Poyatos, et al.
World Journal of Clinical Cases (2020) Vol. 8, Iss. 21, pp. 5250-5283
Open Access | Times Cited: 122
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses
Anna Artese, Valentina Svicher, Giosuè Costa, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100721-100721
Open Access | Times Cited: 98
Botanical drugs and supplements affecting the immune response in the time of COVID‐19: Implications for research and clinical practice
Thomas Brendler, Ahmed Al‐Harrasi, Rudolf Bauer, et al.
Phytotherapy Research (2020) Vol. 35, Iss. 6, pp. 3013-3031
Closed Access | Times Cited: 95
Overview of COVID-19 inflammatory pathogenesis from the therapeutic perspective
Choongho Lee, Won Jun Choi
Archives of Pharmacal Research (2021) Vol. 44, Iss. 1, pp. 99-116
Open Access | Times Cited: 83
A review on potential of natural products in the management of COVID-19
Rudra Chakravarti, Rajveer Singh, Arijit Ghosh, et al.
RSC Advances (2021) Vol. 11, Iss. 27, pp. 16711-16735
Open Access | Times Cited: 79
The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review
Andri Frediansyah
Clinical Epidemiology and Global Health (2021) Vol. 12, pp. 100826-100826
Open Access | Times Cited: 63
SARS-CoV-2 Infection of Airway Epithelial Cells
Gwanghui Ryu, Hyun‐Woo Shin
Immune Network (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 62
COVID‐19: A systematic review and update on prevention, diagnosis, and treatment
Hooman Aghamirza Moghim Aliabadi, Reza Eivazzadeh‐Keihan, Arezoo Beig Parikhani, et al.
MedComm (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 43
A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
Nada A. Ashour, Ayman Abo Elmaaty, Amany A. Sarhan, et al.
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 685-715
Open Access | Times Cited: 40
COVID-19 update: The race to therapeutic development
Julianne D. Twomey, Shen Luo, Alexis Q. Dean, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100733-100733
Open Access | Times Cited: 60
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2
Masoumeh Sadat Mousavi Maleki, Mosayeb Rostamian, Hamid Madanchi
Expert Review of Anti-infective Therapy (2021) Vol. 19, Iss. 10, pp. 1205-1217
Open Access | Times Cited: 51
Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients
Payam Peymani, Tania Dehesh, Farnaz Aligolighasemabadi, et al.
Translational Medicine Communications (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 48
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs
Osama A. Badary
The Pharmacogenomics Journal (2021) Vol. 21, Iss. 3, pp. 275-284
Open Access | Times Cited: 40
Association between angiotensinogen (AGT), angiotensin-converting enzyme (ACE) and angiotensin-II receptor 1 (AGTR1) polymorphisms and COVID-19 infection in the southeast of Iran: a preliminary case-control study
H R Kouhpayeh, Farhad Tabasi, Mohammad Dehvari, et al.
Translational Medicine Communications (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 40
How to use COVID-19 antiviral drugs in patients with chronic kidney disease
Ajinath Kale, Vishwadeep Shelke, Neha Dagar, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 20
Chlorination of antiviral drug ribavirin: Kinetics, nontargeted identification, and concomitant toxicity evolution
Kehui Guo, Yang Liu, Jianfeng Peng, et al.
Journal of Hazardous Materials (2024) Vol. 467, pp. 133478-133478
Closed Access | Times Cited: 5
A new multifunctional electrocatalyst based on PbS nanostructures decorated with graphene/polyaniline-modified glassy carbon electrode for selective detection of non-steroidal anti-inflammatory drug naproxen
Mina Ahmadi-Kashani, Hossein Dehghani
Microchemical Journal (2024) Vol. 200, pp. 110320-110320
Closed Access | Times Cited: 5
SARS-CoV-2 and Coronaviruses: Understanding Transmission, Impact, and Strategies for Prevention and Treatment
Seyede Nafise Tabatabaei, Zahra Keykhaee, Saghi Nooraei, et al.
Drugs and Drug Candidates (2025) Vol. 4, Iss. 1, pp. 5-5
Open Access
A patent review of CYP3A4 inhibitors (2018 - present)
Dong‐Zhu Tu, Xueyan Hu, J. Lei, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
Page 1 - Next Page

Scroll to top